CIR New and Noteworthy
Information about CIR research, vaccines in the news, infectious diseases, and articles featuring CIR staff and faculty.
CIR Research and Articles featuring Faculty & Staff
Next-gen leaders in diarrheal disease: Q&A with Brittany Feijoo
Brittany Feijoo, MSN, FNP-BC, a research associate at the Johns Hopkins Bloomberg School of Public Health, is one of those next-generation leaders. We talked to Brittany about her path from nursing to global health, her research on Shigella in Kenya, and her role models both inside and outside the scientific community.
Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children
In high-income and middle-income countries, two new products have been authorized to prevent RSV in infants. These products are not yet available in low-income and lower-middle-income countries, where most RSV deaths occur. This paper briefly reviews the efficacy, effectiveness, and safety of these products and explores potential pathways to broadening their availability.
Phase 3 Study Results for Tetravalent Dengue Vaccine Published in NEJM
Study results for a phase 3 trial titled: "Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults" were published on February 1, 2024 in the New England Journal of Medicine. CIR's Team FIRE conducted more than 30 trials for the development of the Butantan Dengue Vaccine (Butantan-DV) used in this study. The study was conducted at 16 sites in Brazil and showed that Butantan-DV prevented symptomatic dengue virus 1 and dengue virus 2 through 2 years of follow up.
Learning more about mosquito transmission may help flavivirus vaccine development
An inpatient challenge study being conducted by CIR's team FIRE aims to learn more about how zika is transmitted between them and humans.
Infecting volunteers with dengue virus shows experimental drug’s promise
Study leader Anna Durbin discusses the power and limits of a provocative human challenge trial
Scientists deliberately gave women Zika — here’s why
Findings from a challenge study conducted by CIR's Team FIRE indicate that the two strains of Zika administered in the trial can be safely and effectively used to infect participants in a Zika vaccine trial.
How Human Challenge Trials Accelerate Vaccine Development
Vaccinated, intentionally infected, and sequestered in a hospital unit, volunteers help researchers fast-track promising vaccine candidates.
Vaccines in the News
JHVI Vaccine Day 2024
This year’s subject: Dengue: New Epidemics, New Vaccines will focus on recent Dengue outbreak trends and strides in vaccine development.
FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus
The U.S. Food and Drug Administration approved Ixchiq, the first chikungunya vaccine. Ixchiq is approved for individuals 18 years of age and older who are at increased risk of exposure to chikungunya virus.
COVID-19 vaccination campaign saved 2.4 million lives, according to health economists
A working paper by researchers from the University of Southern California and Brown University analyzed the global impacts of COVID-19 vaccines.
First RSV Vaccine Approved in the US
The U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
Events and Special Interest
We've Moved!
The CIR's East Baltimore location has moved to the Rangos Building!
Effective May 28, 2024 our new address is:
855 N. Wolfe Street Suite 601
Baltimore, MD 21205
Hampton House Farewell Celebration
The Hopkins community celebrates the rich history of Hampton House before its demolition to make way for a new state-of-the-art facility.